Bone: A new endocrine organ at the heart of chronic kidney disease and mineral and bone disorders

The Lancet Diabetes and Endocrinology

Volumn 2, Issue 5, 2014, Pages 427-436

  Vervloet, Marc G ^a   Massy, Ziad A ^b,c   Brandenburg, Vincent M ^d   Mazzaferro, Sandro ^e   Cozzolino, Mario ^f   Ureña Torres, Pablo ^g   Bover, Jordi ^h   Goldsmith, David ⁱ  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b HÔPITAL AMBROISE PARÉ   (France)

^c UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^d UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f UNIVERSITY OF MILAN   (Italy)

^g HÔPITAL NECKER ENFANTS MALADES   (France)

^h FUNDACIÓ PUIGVERT   (Spain)

ⁱ KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; DICKKOPF 1 PROTEIN; FIBROBLAST GROWTH FACTOR 23; INSULIN; KLOTHO PROTEIN; MINERAL; OSTEOCALCIN; OSTEOGENIC PROTEIN 1; PROTEIN ALPHA KLOTHO; SCLEROSTIN; UNCLASSIFIED DRUG; WNT PROTEIN; FARNOQUINONE; ROMOSOZUMAB; VITAMIN K GROUP; BONE MORPHOGENETIC PROTEIN; DKK1 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR; GENETIC MARKER; SIGNAL PEPTIDE; SOST PROTEIN, HUMAN;

BLOOD VESSEL CALCIFICATION; BONE TISSUE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; ENERGY METABOLISM; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; INSULIN SENSITIVITY; METABOLIC REGULATION; NONHUMAN; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN SECRETION; REVIEW; WNT SIGNALING PATHWAY; ATHEROSCLEROSIS; BONE; BONE DISEASE; BONE METABOLISM; BONE MINERAL; CARDIOVASCULAR DISEASE; KIDNEY DISEASE; OSSIFICATION; POSTMENOPAUSE OSTEOPOROSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; CHRONIC KIDNEY FAILURE; GENETIC MARKER; METABOLISM;

BONE AND BONES; BONE DISEASES; BONE MORPHOGENETIC PROTEINS; FIBROBLAST GROWTH FACTORS; GENETIC MARKERS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MINERALS; OSTEOCALCIN; RENAL INSUFFICIENCY, CHRONIC;

EID: 84899669207     PISSN: 22138587     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2213-8587(14)70059-2     Document Type: Review

References (122)

1. Moe S, Drüeke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006, 69:1945-1953. Kidney Disease: Improving Global Outcomes (KDIGO).
2. Slatopolsky E, Martin K, Hruska K Parathyroid hormone metabolism and its potential as a uremic toxin. Am J Physiol 1980, 239:F1-12.
3. Malluche HH, Mawad HW, Monier-Faugere MC Renal osteodystrophy in the first decade of the new millennium: analysis of 630 bone biopsies in black and white patients. J Bone Miner Res 2011, 26:1368-1376.
4. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004, 351:1296-1305.
5. Raggi P, Giachelli C, Bellasi A Interaction of vascular and bone disease in patients with normal renal function and patients undergoing dialysis. Nat Clin Pract Cardiovasc Med 2007, 4:26-33.
6. Tankó LB, Christiansen C, Cox DA, Geiger MJ, McNabb MA, Cummings SR Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J Bone Miner Res 2005, 20:1912-1920.
7. London G, Coyne D, Hruska K, Malluche HH, Martin KJ The new kidney disease: improving global outcomes (KDIGO) guidelines-expert clinical focus on bone and vascular calcification. Clin Nephrol 2010, 74:423-432.
8. Shanahan CM, Crouthamel MH, Kapustin A, Giachelli CM Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ Res 2011, 109:697-711.
9. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009, 113:S1-130. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group.
10. Zanchi C, Locatelli M, Benigni A, et al. Renal expression of FGF23 in progressive renal disease of diabetes and the effect of ace inhibitor. PLoS One 2013, 8:e70775.
11. van Venrooij NA, Pereira RC, Tintut Y, et al. FGF23 protein expression in coronary arteries is associated with impaired kidney function. Nephrol Dial Transplant 2014, published online Jan 23. 10.1093/ndt/gft523.
12. Goetz R, Ohnishi M, Kir S, et al. Conversion of a paracrine fibroblast growth factor into an endocrine fibroblast growth factor. J Biol Chem 2012, 287:29134-29146.
13. Urakawa I, Yamazaki Y, Shimada T, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006, 444:770-774.
14. Razzaque MS, Lanske B The emerging role of the fibroblast growth factor-23-klotho axis in renal regulation of phosphate homeostasis. J Endocrinol 2007, 194:1-10.
15. David V, Dai B, Martin A, Huang J, Han X, Quarles LD Calcium regulates FGF-23 expression in bone. Endocrinology 2013, 154:4469-4482.
16. Quinn SJ, Thomsen AR, Pang JL, et al. Interactions between calcium and phosphorus in the regulation of the production of fibroblast growth factor 23 in vivo. Am J Physiol Endocrinol Metab 2013, 304:E310-E320.
17. Vervloet MG, van Ittersum FJ, Büttler RM, Heijboer AC, Blankenstein MA, ter Wee PM Effects of dietary phosphate and calcium intake on fibroblast growth factor-23. Clin J Am Soc Nephrol 2011, 6:383-389.
18. Adema AY, de Borst MH, Ter Wee PM, Vervloet MG Dietary and pharmacological modification of fibroblast growth factor-23 in chronic kidney disease. J Ren Nutr 2013, the NIGRAM Consortium, published online Nov 9. 10.1053/j.jrn.2013.09.001.
19. Shalhoub V, Shatzen EM, Ward SC, et al. FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J Clin Invest 2012, 122:2543-2553.
20. Frishberg Y, Ito N, Rinat C, et al. Hyperostosis-hyperphosphatemia syndrome: a congenital disorder of O-glycosylation associated with augmented processing of fibroblast growth factor 23. J Bone Miner Res 2007, 22:235-242.
21. Gutiérrez OM, Wolf M, Taylor EN Fibroblast growth factor 23, cardiovascular disease risk factors, and phosphorus intake in the health professionals follow-up study. Clin J Am Soc Nephrol 2011, 6:2871-2878.
22. Isakova T, Wahl P, Vargas GS, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011, 79:1370-1378.
23. Evenepoel P, Meijers BK, de Jonge H, et al. Recovery of hyperphosphatoninism and renal phosphorus wasting one year after successful renal transplantation. Clin J Am Soc Nephrol 2008, 3:1829-1836.
24. Rao M, Jain P, Ojo T, Surya G, Balakrishnan V Fibroblast growth factor and mineral metabolism parameters among prevalent kidney transplant patients. Int J Nephrol 2012, 2012:490623.
25. Shimada T, Urakawa I, Isakova T, et al. Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J Clin Endocrinol Metab 2010, 95:578-585.
26. Hu MC, Shiizaki K, Kuro-o M, Moe OW Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism. Annu Rev Physiol 2013, 75:503-533.
27. Pereira RC, Juppner H, Azucena-Serrano CE, Yadin O, Salusky IB, Wesseling-Perry K Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease. Bone 2009, 45:1161-1168.
28. Martin A, Liu S, David V, et al. Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling. FASEB J 2011, 25:2551-2562.
29. Farrow EG, Yu X, Summers LJ, et al. Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci USA 2011, 108:E1146-E1155.
30. Gutiérrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008, 359:584-592.
31. Isakova T, Xie H, Yang W, et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011, 305:2432-2439. the Chronic Renal Insufficiency Cohort (CRIC) Study Group.
32. Baia LC, Humalda JK, Vervloet MG, Navis G, Bakker SJ, de Borst MH Fibroblast growth factor 23 and cardiovascular mortality after kidney transplantation. Clin J Am Soc Nephrol 2013, 8:1968-1978. the NIGRAM Consortium.
33. Jovanovich A, Ix JH, Gottdiener J, et al. Fibroblast growth factor 23, left ventricular mass, and left ventricular hypertrophy in community-dwelling older adults. Atherosclerosis 2013, 231:114-119.
34. Faul C, Amaral AP, Oskouei B, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011, 121:4393-4408.
35. Scialla JJ, Lau WL, Reilly MP, et al. Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. Kidney Int 2013, 83:1159-1168. the Chronic Renal Insufficiency Cohort Study Investigators.
36. Nakayama M, Kaizu Y, Nagata M, et al. Fibroblast growth factor 23 is associated with carotid artery calcification in chronic kidney disease patients not undergoing dialysis: a cross-sectional study. BMC Nephrol 2013, 14:22.
37. Schoppet M, Hofbauer LC, Brinskelle-Schmal N, et al. Serum level of the phosphaturic factor FGF23 is associated with abdominal aortic calcification in men: the STRAMBO study. J Clin Endocrinol Metab 2012, 97:E575-E583.
38. Desjardins L, Liabeuf S, Renard C, et al. FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages. Osteoporos Int 2012, 23:2017-2025. the European Uremic Toxin (EUTox) Work Group.
39. Moldovan D, Moldovan I, Rusu C, Kacso I, Patiu IM, Gherman-Caprioara M FGF-23, vascular calcification, and cardiovascular diseases in chronic hemodialysis patients. Int Urol Nephrol 2014, 46:121-128.
40. Lim K, Lu TS, Molostvov G, et al. Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23. Circulation 2012, 125:2243-2255.
41. Zhu D, Mackenzie NC, Millan JL, Farquharson C, MacRae VE A protective role for FGF-23 in local defence against disrupted arterial wall integrity?. Mol Cell Endocrinol 2013, 372:1-11.
42. Lindberg K, Olauson H, Amin R, et al. Arterial klotho expression and FGF23 effects on vascular calcification and function. PLoS One 2013, 8:e60658.
43. Ärnlöv J, Carlsson AC, Sundström J, et al. Serum FGF23 and risk of cardiovascular events in relation to mineral metabolism and cardiovascular pathology. Clin J Am Soc Nephrol 2013, 8:781-786.
44. Yilmaz MI, Sonmez A, Saglam M, et al. Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial. Am J Kidney Dis 2012, 59:177-185.
45. 2+ pathway: a new vertebrate Wnt signaling pathway takes shape. Trends Genet 2000, 16:279-283.
46. Monroe DG, McGee-Lawrence ME, Oursler MJ, Westendorf JJ Update on Wnt signaling in bone cell biology and bone disease. Gene 2012, 492:1-18.
47. Marinou K, Christodoulides C, Antoniades C, Koutsilieris M Wnt signaling in cardiovascular physiology. Trends Endocrinol Metab 2012, 23:628-636.
48. Ke HZ, Richards WG, Li X, Ominsky MS Sclerostin and dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev 2012, 33:747-783.
49. Stevens KK, Beattie EC, Delles C, Jardine AG. Phosphate impairs endothelial function-a mechanism for increased cardiovascular risk? ERA-EDTA 50th Congress; Istanbul, Turkey; May 18-21, 2013. SO-018.
50. Cejka D, Herberth J, Branscum AJ, et al. Sclerostin and Dickkopf-1 in renal osteodystrophy. Clin J Am Soc Nephrol 2011, 6:877-882.
51. Brandenburg VM, Kramann R, Koos R, et al. Relationship between sclerostin and cardiovascular calcification in hemodialysis patients: a cross-sectional study. BMC Nephrol 2013, 14:219.
52. Gifre L, Ruiz-Gaspà S, Monegal A, et al. Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover. Bone 2013, 57:272-276.
53. Mukhopadhyay M, Shtrom S, Rodriguez-Esteban C, et al. Dickkopf1 is required for embryonic head induction and limb morphogenesis in the mouse. Dev Cell 2001, 1:423-434.
54. Poole KE, van Bezooijen RL, Loveridge N, et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J 2005, 19:1842-1844.
55. Kamiya N The role of BMPs in bone anabolism and their potential targets SOST and DKK1. Curr Mol Pharmacol 2012, 5:153-163.
56. Krause C, Korchynskyi O, de Rooij K, et al. Distinct modes of inhibition by sclerostin on bone morphogenetic protein and Wnt signaling pathways. J Biol Chem 2010, 285:41614-41626.
57. Boyden LM, Mao J, Belsky J, et al. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 2002, 346:1513-1521.
58. Babij P, Zhao W, Small C, et al. High bone mass in mice expressing a mutant LRP5 gene. J Bone Miner Res 2003, 18:960-974.
59. Balemans W, Patel N, Ebeling M, et al. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet 2002, 39:91-97.
60. Morvan F, Boulukos K, Clément-Lacroix P, et al. Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J Bone Miner Res 2006, 21:934-945.
61. Winkler DG, Sutherland MK, Geoghegan JC, et al. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 2003, 22:6267-6276.
62. Yao GQ, Wu JJ, Troiano N, Insogna K Targeted overexpression of Dkk1 in osteoblasts reduces bone mass but does not impair the anabolic response to intermittent PTH treatment in mice. J Bone Miner Metab 2011, 29:141-148.
63. Kramer I, Loots GG, Studer A, Keller H, Kneissel M Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice. J Bone Miner Res 2010, 25:178-189.
64. Thambiah S, Roplekar R, Manghat P, et al. Circulating sclerostin and dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness. Calcif Tissue Int 2012, 90:473-480.
65. Sabbagh Y, Graciolli FG, O'Brien S, et al. Repression of osteocyte Wnt/β-catenin signaling is an early event in the progression of renal osteodystrophy. J Bone Miner Res 2012, 27:1757-1772.
66. Al-Chaqmaqchi HA, Moshfegh A, Dadfar E, et al. Activation of Wnt/β-catenin pathway in monocytes derived from chronic kidney disease patients. PLoS One 2013, 8:e68937.
67. Mani A, Radhakrishnan J, Wang H, et al. LRP6 mutation in a family with early coronary disease and metabolic risk factors. Science 2007, 315:1278-1282.
68. Mill C, George SJ Wnt signalling in smooth muscle cells and its role in cardiovascular disorders. Cardiovasc Res 2012, 95:233-240.
69. Zhu D, Mackenzie NC, Millán JL, Farquharson C, MacRae VE The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells. PLoS One 2011, 6:e19595.
70. Kramann R, Brandenburg VM, Schurgers LJ, et al. Novel insights into osteogenesis and matrix remodelling associated with calcific uraemic arteriolopathy. Nephrol Dial Transplant 2013, 28:856-868.
71. Cannata-Andía JB, Rodriguez García M, Gómez Alonso C Osteoporosis and adynamic bone in chronic kidney disease. J Nephrol 2013, 26:73-80.
72. McClung MR, Grauer A, Boonen S, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 2014, 370:412-420.
73. Wellendorph P, Bräuner-Osborne H Molecular cloning, expression, and sequence analysis of GPRC6A, a novel family C G-protein-coupled receptor. Gene 2004, 335:37-46.
74. Neve A, Corrado A, Cantatore FP Osteocalcin: skeletal and extra-skeletal effects. J Cell Physiol 2013, 228:1149-1153.
75. Gundberg CM, Nieman SD, Abrams S, Rosen H Vitamin K status and bone health: an analysis of methods for determination of undercarboxylated osteocalcin. J Clin Endocrinol Metab 1998, 83:3258-3266.
76. Coen G, Mazzaferro S, Bonucci E, et al. Bone GLA protein in predialysis chronic renal failure. Effects of 1,25(OH)2D3 administration in a long-term follow-up. Kidney Int 1985, 28:783-790.
77. Malluche HH, Faugere MC, Fanti P, Price PA Plasma levels of bone Gla-protein reflect bone formation in patients on chronic maintenance dialysis. Kidney Int 1984, 26:869-874.
78. Lee NK, Sowa H, Hinoi E, et al. Endocrine regulation of energy metabolism by the skeleton. Cell 2007, 130:456-469.
79. Booth SL, Centi A, Smith SR, Gundberg C The role of osteocalcin in human glucose metabolism: marker or mediator?. Nat Rev Endocrinol 2013, 9:43-55.
80. Sokoll LJ, Booth SL, O'Brien ME, Davidson KW, Tsaioun KI, Sadowski JA Changes in serum osteocalcin, plasma phylloquinone, and urinary γ-carboxyglutamic acid in response to altered intakes of dietary phylloquinone in human subjects. Am J Clin Nutr 1997, 65:779-784.
81. Confavreux CB, Borel O, Lee F, et al. Osteoid osteoma is an osteocalcinoma affecting glucose metabolism. Osteoporos Int 2012, 23:1645-1650.
82. Schafer AL, Sellmeyer DE, Schwartz AV, et al. Change in undercarboxylated osteocalcin is associated with changes in body weight, fat mass, and adiponectin: parathyroid hormone (1-84) or alendronate therapy in postmenopausal women with osteoporosis (the PaTH study). J Clin Endocrinol Metab 2011, 96:E1982-E1989.
83. Schwartz AV, Schafer AL, Grey A, et al. Effects of antiresorptive therapies on glucose metabolism: results from the FIT, HORIZON-PFT, and FREEDOM trials. J Bone Miner Res 2013, 28:1348-1354.
84. Holden RM, Morton AR, Garland JS, Pavlov A, Day AG, Booth SL Vitamins K and D status in stages 3-5 chronic kidney disease. Clin J Am Soc Nephrol 2010, 5:590-597.
85. McCabe KM, Booth SL, Fu X, et al. Dietary vitamin K and therapeutic warfarin alter the susceptibility to vascular calcification in experimental chronic kidney disease. Kidney Int 2013, 83:835-844.
86. Okuno S, Ishimura E, Tsuboniwa N, et al. Significant inverse relationship between serum undercarboxylated osteocalcin and glycemic control in maintenance hemodialysis patients. Osteoporos Int 2013, 24:605-612.
87. Bacchetta J, Boutroy S, Guebre-Egziabher F, et al. The relationship between adipokines, osteocalcin and bone quality in chronic kidney disease. Nephrol Dial Transplant 2009, 24:3120-3125.
88. Westenfeld R, Krueger T, Schlieper G, et al. Effect of vitamin K2 supplementation on functional vitamin K deficiency in hemodialysis patients: a randomized trial. Am J Kidney Dis 2012, 59:186-195.
89. Urist MR Bone: formation by autoinduction. Science 1965, 150:893-899.
90. Sampath TK, Muthukumaran N, Reddi AH Isolation of osteogenin, an extracellular matrix-associated, bone-inductive protein, by heparin affinity chromatography. Proc Natl Acad Sci USA 1987, 84:7109-7113.
91. Wang EA, Rosen V, Cordes P, et al. Purification and characterization of other distinct bone-inducing factors. Proc Natl Acad Sci USA 1988, 85:9484-9488.
92. Hogan BL Bone morphogenetic proteins: multifunctional regulators of vertebrate development. Genes Dev 1996, 10:1580-1594.
93. Rennenberg RJ, Schurgers LJ, Kroon AA, Stehouwer CD Arterial calcifications. J Cell Mol Med 2010, 14:2203-2210.
94. Kim M, Choe S BMPs and their clinical potentials. BMB Rep 2011, 44:619-634.
95. Kingsley DM The TGF-β superfamily: new members, new receptors, and new genetic tests of function in different organisms. Genes Dev 1994, 8:133-146.
96. Heldin CH, Miyazono K, ten Dijke P TGF-β signalling from cell membrane to nucleus through SMAD proteins. Nature 1997, 390:465-471.
97. Miyazono K Signal transduction by bone morphogenetic protein receptors: functional roles of Smad proteins. Bone 1999, 25:91-93.
98. Hruska KA, Mathew S, Saab G Bone morphogenetic proteins in vascular calcification. Circ Res 2005, 97:105-114.
99. Shao JS, Cai J, Towler DA Molecular mechanisms of vascular calcification: lessons learned from the aorta. Arterioscler Thromb Vasc Biol 2006, 26:1423-1430.
100. Li X, Yang HY, Giachelli CM BMP-2 promotes phosphate uptake, phenotypic modulation, and calcification of human vascular smooth muscle cells. Atherosclerosis 2008, 199:271-277.
101. Parhami F, Morrow AD, Balucan J, et al. Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation. A possible explanation for the paradox of arterial calcification in osteoporotic patients. Arterioscler Thromb Vasc Biol 1997, 17:680-687.
102. Fukui N, Zhu Y, Maloney WJ, Clohisy J, Sandell LJ Stimulation of BMP-2 expression by pro-inflammatory cytokines IL-1 and TNF-α in normal and osteoarthritic chondrocytes. J Bone Joint Surg Am 2003, 85-A(suppl 3):59-66.
103. Zebboudj AF, Shin V, Boström K Matrix GLA protein and BMP-2 regulate osteoinduction in calcifying vascular cells. J Cell Biochem 2003, 90:756-765.
104. Boström K, Tsao D, Shen S, Wang Y, Demer LL Matrix GLA protein modulates differentiation induced by bone morphogenetic protein-2 in C3H10T1/2 cells. J Biol Chem 2001, 276:14044-14052.
105. Galvin KM, Donovan MJ, Lynch CA, et al. A role for smad6 in development and homeostasis of the cardiovascular system. Nat Genet 2000, 24:171-174.
106. Dalfino G, Simone S, Porreca S, et al. Bone morphogenetic protein-2 may represent the molecular link between oxidative stress and vascular stiffness in chronic kidney disease. Atherosclerosis 2010, 211:418-423.
107. Vukicevic S, Basic V, Rogic D, et al. Osteogenic protein-1 (bone morphogenetic protein-7) reduces severity of injury after ischemic acute renal failure in rat. J Clin Invest 1998, 102:202-214.
108. Hruska KA, Guo G, Wozniak M, et al. Osteogenic protein-1 prevents renal fibrogenesis associated with ureteral obstruction. Am J Physiol Renal Physiol 2000, 279:F130-F143.
109. Wang S, Chen Q, Simon TC, et al. Bone morphogenic protein-7 (BMP-7), a novel therapy for diabetic nephropathy. Kidney Int 2003, 63:2037-2049.
110. Zeisberg M, Hanai J, Sugimoto H, et al. BMP-7 counteracts TGF-β1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 2003, 9:964-968.
111. Mathew S, Davies M, Lund R, Saab G, Hruska KA Function and effect of bone morphogenetic protein-7 in kidney bone and the bone-vascular links in chronic kidney disease. Eur J Clin Invest 2006, 36(suppl 2):43-50.
112. Davies MR, Lund RJ, Hruska KA BMP-7 is an efficacious treatment of vascular calcification in a murine model of atherosclerosis and chronic renal failure. J Am Soc Nephrol 2003, 14:1559-1567.
113. Davies MR, Lund RJ, Mathew S, Hruska KA Low turnover osteodystrophy and vascular calcification are amenable to skeletal anabolism in an animal model of chronic kidney disease and the metabolic syndrome. J Am Soc Nephrol 2005, 16:917-928.
114. Tossidou I, Schiffer M TGF-β/BMP pathways and the podocyte. Semin Nephrol 2012, 32:368-376.
115. Smith ER, Ford ML, Tomlinson LA, Rajkumar C, McMahon LP, Holt SG Phosphorylated fetuin-A-containing calciprotein particles are associated with aortic stiffness and a procalcific milieu in patients with pre-dialysis CKD. Nephrol Dial Transplant 2012, 27:1957-1966.
116. Eckardt KU, Coresh J, Devuyst O, et al. Evolving importance of kidney disease: from subspecialty to global health burden. Lancet 2013, 382:158-169.
117. Crepaldi G, Maggi S Epidemiologic link between osteoporosis and cardiovascular disease. J Endocrinol Invest 2009, 32(suppl):2-5.
118. Lampropoulos CE, Papaioannou I, D'Cruz DP Osteoporosis-a risk factor for cardiovascular disease?. Nat Rev Rheumatol 2012, 8:587-598.
119. den Uyl D, Nurmohamed MT, van Tuyl LH, Raterman HG, Lems WF (Sub)clinical cardiovascular disease is associated with increased bone loss and fracture risk; a systematic review of the association between cardiovascular disease and osteoporosis. Arthritis Res Ther 2011, 13:R5.
120. Thompson B, Towler DA Arterial calcification and bone physiology: role of the bone-vascular axis. Nat Rev Endocrinol 2012, 8:529-543.
121. Fadini GP, Rattazzi M, Matsumoto T, Asahara T, Khosla S Emerging role of circulating calcifying cells in the bone-vascular axis. Circulation 2012, 125:2772-2781.
122. Wolf M Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int 2012, 82:737-747.